Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

Astrazeneca,U.s.,Headquarters,In,Wilmington,,De,,Usa,,November,5,,2023.

On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the ​BaxHTN Phase 3 trial evaluating ​baxdrostat. The company released the topline data in July.

The study showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.